Skip to content
Review Open access

Beyond AUC: a clinician’s guide to building and trusting prediction models in oncology—a narrative review

Jul 2026 · Frontiers in Oncology · Vol 16 · 1 citation · 47 references
Medicine

TL;DR

This review provides a practical, clinician-oriented guide to the statistical principles and advanced methods for developing, validating, and interpreting robust prediction models and synthesized key statistical principles and illustrative examples to guide clinicians and researchers through model development, validation, interpretation, and clinical translation.

Abstract

Background Prediction models are central to advancing precision oncology, yet many fail to translate into clinical practice due to methodological flaws and inadequate validation. This review provides a practical, clinician-oriented guide to the statistical principles and advanced methods for developing, validating, and interpreting robust prediction models. Methods This narrative review used a targeted literature search of PubMed, Embase, and Web of Science to identify methodological papers, reporting guidelines, and representative oncology prediction model studies, with a focus on literature published between January 1, 2005, and February 28, 2025. Landmark methodological papers published before 2005 were also included when directly relevant. Rather than performing a systematic review or meta-analysis, we synthesized key statistical principles and illustrative examples to guide clinicians and researchers through model development, validation, interpretation, and clinical translation. Findings A multifaceted evaluation encompassing discrimination, calibration, clinical utility, and external validation is essential for prediction models. Over-reliance on discrimination metrics such as the area under the receiver operating characteristic curve (AUC), while neglecting calibration and clinical utility, can lead to misleading conclusions about a model’s value. Rigorous external validation in geographically or temporally distinct cohorts is the most direct test of generalizability, and performance degradation should be interpreted through root-cause analysis rather than treated simply as model failure. Key challenges include managing overfitting, selecting appropriate modeling and validation strategies for different oncology scenarios, addressing special settings such as rare tumors and real-world data, and improving the interpretability of complex “black-box” models. Conclusion Building a trustworthy prediction model requires a combination of advanced computational methods and rigorous statistical principles. To bridge the gap from model development to clinical impact, researchers must prioritize comprehensive validation, transparent reporting, scenario-appropriate modeling decisions, and critical assessment of a model’s real-world utility.

Read PDF

Similar papers

Review Open access Aug 2026

Reporting of external validation studies needs improvement: a systematic review of reporting in oncology prediction model studies.

External validation studies were substantially less common than prediction model development studies and reporting of key methodological and performance details were frequently incomplete despite the availability of TRIPOD, suggesting it may sometimes be treated as a procedural step rather than a study designed to eval...

Rebecca Whittle, A. Legha, Biruk Tsegaye et al. · 0 citations
Review Open access Jul 2026

Predicting, describing, or measuring? How to align model purpose with validity and applicability in critical care outcome research.

PURPOSE OF REVIEW Clinical models are commonly applied in critical care for both descriptive and predictive purposes. However, methodological rigour is often lacking in their development and validation. This review examines the principles underlying the multiple domains of model validity. We argue that a clear model pu...

A. Tracy, Aasiyah Rashan, O. Ranzani · 0 citations
Review Open access Aug 2026

Beyond the P Value: A Systematic Framework for Interpreting Oncology Clinical Trials

A structured framework to evaluate late-phase trials beyond simple P value assessments is developed and empowers researchers to rescue therapies with latent clinical benefit or confidently confirm futility, thereby optimizing the evidence landscape for precision oncology.

Ruyue Li, Xue Dong, Xiujing Yao et al. · 0 citations
Conference Open access Aug 2026

The Quality of Research Methods in Studies Quantifying the Association Between Cancer Diagnosis to Treatment Interval and Overall Survival

A systematic review of observational studies published from 2020 onward that examine the association between DTI and OS in seven cancers with global relevance to provide a comprehensive assessment of methodological validity and consistency in recent studies investigating the association between cancer DTI and OS.

V. Patel · 0 citations
Review Aug 2026

Beyond predictive performance: A systematic review and critical methodological appraisal of AI/ML and conventional modelling strategies in breast, colorectal, and pancreatic Cancer.

AI/ML adds the most methodological value in imaging-derived feature extraction and nonlinear perioperative prediction, while conventional regression remains preferable in large, structured datasets with linear predictors.

N. Abidin, N. Shariff, Eva Nabiha Zamri et al. · 0 citations
Review Open access Aug 2026

Assessing real-world evidence utilization in oncology health technology assessments: insights from external control-arm studies

Data source selection, patient population comparison, and transparent presentation of potential biases were important factors in enhancing the credibility and utility of RWD-based ECAs in HTA decision-making processes.

Gleicy Macedo Hair, M. Hanisch, S. Mt-Isa et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.